

# Tadej Battelino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2525591/publications.pdf>

Version: 2024-02-01

273  
papers

14,201  
citations

38660

50  
h-index

23472

111  
g-index

295  
all docs

295  
docs citations

295  
times ranked

11799  
citing authors

#	ARTICLE	IF	CITATIONS
1	Osilodrostat for Cushing Disease and Its Role in Pediatrics. <i>Hormone Research in Paediatrics</i> , 2023, 96, 573-580.	0.8	3
2	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1226-1242.	1.3	69
3	Guideline Development for Medical Device Technology: Issues for Consideration. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1698-1710.	1.3	2
4	Real-World Performance of the MiniMed <sup>®</sup> 780G System: First Report of Outcomes from 4120 Users. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 113-119.	2.4	110
5	Glycaemic management in diabetes: old and new approaches. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 75-84.	5.5	50
6	Clinical and genetic characteristics of two patients with tyrosinemia type 1 in Slovenia – A novel fumarylacetoacetate hydrolase (FAH) intronic disease-causing variant. <i>Molecular Genetics and Metabolism Reports</i> , 2022, 30, 100836.	0.4	2
7	Data on phenylalanine-to-tyrosine ratios in assessment of tetrahydrobiopterin (BH4)-responsiveness in patients with hyperphenylalaninemia. <i>Data in Brief</i> , 2022, 41, 107926.	0.5	1
8	RESCUE Collaborative Community: A New Initiative to Reduce Rates of Intended Self-Injury and Suicide Among People with Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 583-587.	2.4	2
9	Global impact of COVID-19 on newborn screening programmes. <i>BMJ Global Health</i> , 2022, 7, e007780.	2.0	11
10	Optimizing the Phenylalanine Cut-Off Value in a Newborn Screening Program. <i>Genes</i> , 2022, 13, 517.	1.0	4
11	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	2.7	8
12	A Novel Splice-Site Deletion in the POU1F1 Gene Causes Combined Pituitary Hormone Deficiency in Multiple Sudanese Pedigrees. <i>Genes</i> , 2022, 13, 657.	1.0	1
13	Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe. <i>European Journal of Endocrinology</i> , 2022, 186, K17-K24.	1.9	7
14	International comparison of glycaemic control in people with type 1 diabetes: an update and extension. <i>Diabetic Medicine</i> , 2022, 39, e14766.	1.2	28
15	Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1357-1367.	1.8	20
16	Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 real-world users. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1370-1379.	2.2	73
17	Pathogenesis of Type 1 Diabetes: Established Facts and New Insights. <i>Genes</i> , 2022, 13, 706.	1.0	19
18	Long-Term Follow-Up of Three Family Members with a Novel NNT Pathogenic Variant Causing Primary Adrenal Insufficiency. <i>Genes</i> , 2022, 13, 717.	1.0	6

#	ARTICLE	IF	CITATIONS
19	The Role of Epigenetic Modifications in Late Complications in Type 1 Diabetes. <i>Genes</i> , 2022, 13, 705.	1.0	11
20	Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 407-417.	5.5	30
21	Continuous and Intermittent Glucose Monitoring in 2021. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, S-209-S-219.	2.4	1
22	Heterozygous Genetic Variants in Autosomal Recessive Genes of the Leptin-Melanocortin Signalling Pathway Are Associated With the Development of Childhood Obesity. <i>Frontiers in Endocrinology</i> , 2022, 13, 832911.	1.5	8
23	An Adolescent Boy with Klinefelter Syndrome and 47,XXY/46,XX Mosaicism: Case Report and Review of Literature. <i>Genes</i> , 2022, 13, 744.	1.0	1
24	Towards Achieving Equity and Innovation in Newborn Screening across Europe. <i>International Journal of Neonatal Screening</i> , 2022, 8, 31.	1.2	14
25	Heterozygous NPR2 Variants in Idiopathic Short Stature. <i>Genes</i> , 2022, 13, 1065.	1.0	4
26	Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 848-852.	2.4	4
27	Glucagon-like peptide-1, a matter of taste?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 763-775.	2.6	8
28	Comparison of Second-Generation Basal Insulin Analogs: A Review of the Evidence from Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 20-30.	2.4	6
29	Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 599-608.	2.2	36
30	The Digital/Virtual Diabetes Clinic: The Future Is Now? Recommendations from an International Panel on Diabetes Digital Technologies Introduction. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 146-154.	2.4	79
31	A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. <i>Lancet</i> , 2021, 397, 208-219.	6.3	206
32	Time in range centered diabetes care. <i>Clinical Pediatric Endocrinology</i> , 2021, 30, 1-10.	0.4	28
33	Lower HbA1c targets are associated with better metabolic control. <i>European Journal of Pediatrics</i> , 2021, 180, 1513-1520.	1.3	10
34	Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]. <i>Diabetologia</i> , 2021, 64, 935-938.	2.9	4
35	The SWEET Project 10-Year Benchmarking in 19 Countries Worldwide Is Associated with Improved HbA1c and Increased Use of Diabetes Technology in Youth with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 491-499.	2.4	59
36	Central TSH Dysregulation in a Patient with Familial Non-Autoimmune Autosomal Dominant Hyperthyroidism Due to a Novel Thyroid-Stimulating Hormone Receptor Disease-Causing Variant. <i>Medicina (Lithuania)</i> , 2021, 57, 196.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Very Long-Chain Acyl-CoA Dehydrogenase Deficiency: High Incidence of Detected Patients With Expanded Newborn Screening Program. <i>Frontiers in Genetics</i> , 2021, 12, 648493.	1.1	4
38	Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	185
39	Once-Weekly Somapacitan Versus Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Efficacy Results From REAL 3, a Randomized Phase 2 Trial. <i>Journal of the Endocrine Society</i> , 2021, 5, A680-A680.	0.1	0
40	Next-Generation Sequencing in Newborn Screening: A Review of Current State. <i>Frontiers in Genetics</i> , 2021, 12, 662254.	1.1	37
41	Current Status of Newborn Screening in Southeastern Europe. <i>Frontiers in Pediatrics</i> , 2021, 9, 648939.	0.9	10
42	Carer's Attachment Anxiety, Stressful Life-Events and the Risk of Childhood-Onset Type 1 Diabetes. <i>Frontiers in Psychiatry</i> , 2021, 12, 657982.	1.3	3
43	Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial. <i>Pediatric Diabetes</i> , 2021, 22, 734-741.	1.2	26
44	Two Cases With an Early Presented Proopiomelanocortin Deficiency—A Long-Term Follow-Up and Systematic Literature Review. <i>Frontiers in Endocrinology</i> , 2021, 12, 689387.	1.5	17
45	Continuous and Intermittent Glucose Monitoring in 2020. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, S-16-S-31.	2.4	0
46	Novel Insights Into Monogenic Obesity Syndrome Due to INPP5E Gene Variant: A Case Report of a Female Patient. <i>Frontiers in Endocrinology</i> , 2021, 12, 581134.	1.5	4
47	Psychological Outcomes and Predictors of Weight Loss in Adolescents With Severe Obesity Following a Reversible Endoscopic Bariatric Procedure. <i>Frontiers in Pediatrics</i> , 2021, 9, 688287.	0.9	1
48	Validation of the Lifetime Incidence of Traumatic Events (LITE-S/P) Questionnaires in Children and Adolescents in Slovenia. <i>Frontiers in Psychiatry</i> , 2021, 12, 665315.	1.3	1
49	Missed and Mistimed Insulin Doses in People with Diabetes: A Systematic Literature Review. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 844-856.	2.4	22
50	Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial. <i>Trials</i> , 2021, 22, 464.	0.7	4
51	Drafting a blueprint for the design of a rare disease ecosystem in Slovenia: Identifying salient opportunities and outlining policy recommendations. <i>Journal of Global Health</i> , 2021, 11, 03064.	1.2	0
52	Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108935.	1.1	9
53	Randomised Controlled Trials in Diabetes Research: A Pathway to Interpreting Published Results. <i>Diabetes Therapy</i> , 2021, 12, 2635-2644.	1.2	0
54	Therapy-type related long-term outcomes in mucopolysaccharidosis type II (Hunter syndrome) – Case series. <i>Molecular Genetics and Metabolism Reports</i> , 2021, 28, 100779.	0.4	1

#	ARTICLE	IF	CITATIONS
55	Detection of Del/Dup Inside SHOX/PAR1 Region in Children and Young Adults with Idiopathic Short Stature. <i>Genes</i> , 2021, 12, 1546.	1.0	2
56	Reye Syndrome with Severe Hyperammonemia and a Good Neurological Outcome. <i>American Journal of Case Reports</i> , 2021, 22, e932864.	0.3	0
57	Sex-Related Differences in Cardiovascular Disease Risk Profile in Children and Adolescents with Type 1 Diabetes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10192.	1.8	10
58	Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study. <i>Hormone Research in Paediatrics</i> , 2021, 94, 133-143.	0.8	6
59	Letter to the Editor From SÄvendahl et al.: â€œWeekly Lonapegsomatropin in Treatment-NaÃ¼ve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trialâ€. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, , .	1.8	2
60	Hybrid Closed-Loop Systems for the Treatment of Type 1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe. <i>Diabetes Therapy</i> , 2021, 12, 3107-3135.	1.2	16
61	Towards a Comprehensive Strategy for the Management of Rare Diseases in Slovenia: Outlining an IT-Enabled Ecosystemic Approach. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12395.	1.2	1
62	Altered Taste Function in Young Individuals With Type 1 Diabetes. <i>Frontiers in Nutrition</i> , 2021, 8, 797920.	1.6	3
63	Technological Approaches in the Analysis of Extracellular Vesicle Nucleotide Sequences. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 787551.	2.0	5
64	Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial. <i>Diabetes Care</i> , 2020, 43, 29-36.	4.3	68
65	Evolution of Diabetes Technology. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 1-18.	1.2	44
66	Relevant Weight Reduction and Reversed Metabolic Co-morbidities Can Be Achieved by Duodenojejunal Bypass Liner in Adolescents with Morbid Obesity. <i>Obesity Surgery</i> , 2020, 30, 1001-1010.	1.1	3
67	Normalization of obstructive cardiomyopathy and improvement of hepatopathy on ketogenic diet in patient with glycogen storage disease (GSD) type IIIa. <i>Molecular Genetics and Metabolism Reports</i> , 2020, 24, 100628.	0.4	9
68	Continuous Glucose Monitoringâ€”â€œDerived Data Reportâ€ Simply a Better Management Tool. <i>Diabetes Care</i> , 2020, 43, 2327-2329.	4.3	15
69	Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). <i>Diabetologia</i> , 2020,	2.9	102
70	Glucose management for exercise using continuous glucose monitoring ( <scp>CGM</scp> ) and intermittently scanned <scp>CGM</scp> ( <scp>isCGM</scp> ) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes ( <scp>EASD</scp> ) and of the International Society for Pediatric and Adolescent Diabetes ( <scp>ISPAD</scp> ) endorsed by <scp>. <i>Pediatric Diabetes</i> , 2020, 21, 1375-1393.	1.2	46
71	Data highlighting effects of Ketogenic diet on cardiomyopathy and hepatopathy in Glycogen storage disease Type IIIA. <i>Data in Brief</i> , 2020, 32, 106205.	0.5	2
72	High-Sensitivity C-Reactive Protein and Carotid Intima Media Thickness as Markers of Subclinical Inflammation and Atherosclerosis in Pediatric Patients with Hypercholesterolemia. <i>Molecules</i> , 2020, 25, 5118.	1.7	8

#	ARTICLE	IF	CITATIONS
73	Glycemic Variability: The Danger of a Physiologically Stable Metric. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3815-e3817.	1.8	8
74	Genetic and Clinical Characteristics of Patients With Homozygous and Compound Heterozygous Familial Hypercholesterolemia From Three Different Populations: Case Series. <i>Frontiers in Genetics</i> , 2020, 11, 572176.	1.1	3
75	Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. <i>Nature Medicine</i> , 2020, 26, 1380-1384.	15.2	127
76	A patient with glycogen storage disease type 0 and a novel sequence variant in GYS2: a case report and literature review. <i>Journal of International Medical Research</i> , 2020, 48, 030006052093685.	0.4	8
77	Hypercholesterolemia in Two Siblings with Resistance to Thyroid Hormones Due to Disease-Causing Variant in Thyroid Hormone Receptor (THRB) Gene. <i>Medicina (Lithuania)</i> , 2020, 56, 699.	0.8	1
78	Carotid Intima-Media Thickness in Healthy Children and Adolescents: Normative Data and Systematic Literature Review. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 597768.	1.1	32
79	Case Report: Liver Transplantation in Homozygous Familial Hypercholesterolemia (HoFH)â€™Long-Term Follow-Up of a Patient and Literature Review. <i>Frontiers in Pediatrics</i> , 2020, 8, 567895.	0.9	12
80	Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6â€™17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial. <i>Diabetes Care</i> , 2020, 43, 1512-1519.	4.3	11
81	Acute Hyperglycemia and Spatial Working Memory in Adolescents With Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1941-1944.	4.3	28
82	Prevalence of Endocrine and Metabolic Comorbidities in a National Cohort of Patients with Craniopharyngioma. <i>Hormone Research in Paediatrics</i> , 2020, 93, 46-57.	0.8	17
83	IL-22 Paucity in APECED Is Associated With Mucosal and Microbial Alterations in Oral Cavity. <i>Frontiers in Immunology</i> , 2020, 11, 838.	2.2	14
84	Introduction to SMBG. , 2020, , 3-31.		0
85	InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoringâ€™Study Design. <i>Diabetes Therapy</i> , 2020, 11, 1017-1027.	1.2	15
86	Continuous and Intermittent Glucose Monitoring in 2019. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, S-3-S-16.	2.4	2
87	Closed-loop insulin delivery systems in children and adolescents with type 1 diabetes. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 157-166.	2.4	11
88	Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1847-e1861.	1.8	37
89	Extracellular Vesicles Derived Human-miRNAs Modulate the Immune System in Type 1 Diabetes. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 202.	1.8	29
90	Anthropometry and bone mineral density in treated and untreated hyperphenylalaninemia. <i>Endocrine Connections</i> , 2020, 9, 649-657.	0.8	2

#	ARTICLE	IF	CITATIONS
91	180-OR: Dasiglucagon as a Fast and Effective Treatment for Severe Hypoglycemia in Children with Diabetes. <i>Diabetes</i> , 2020, 69, 180-OR.	0.3	3
92	New technical approach to the diabetes therapy. <i>Minerva Pediatrica</i> , 2020, 72, 263-277.	2.6	3
93	Expanded newborn screening program in Slovenia using tandem mass spectrometry and confirmatory next generation sequencing genetic testing. <i>Zdravstveno Varstvo</i> , 2020, 59, 256-263.	0.6	17
94	Nationwide digital/virtual diabetes care of children, adolescents and young adults with type 1 diabetes during a COVID-19 pandemic in Slovenia. <i>ZdravniÅiki Vestnik</i> , 2020, 89, 626-633.	0.1	2
95	Precocious puberty in a girl with 3-methylglutaconic aciduria type 1 (3-MGA-I) due to a novel AUH gene mutation. <i>Molecular Genetics and Metabolism Reports</i> , 2020, 25, 100691.	0.4	3
96	Charting Early Developmental Trajectory of a Pilot Rare Disease Registry in Slovenia. <i>Studies in Health Technology and Informatics</i> , 2020, 272, 213-216.	0.2	0
97	Development of a pilot rare disease registry: a focus group study of initial steps towards the establishment of a rare disease ecosystem in Slovenia. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 172.	1.2	18
98	Impact of attention deficit hyperactivity disorder on metabolic control in adolescents with type1 diabetes. <i>Journal of Psychosomatic Research</i> , 2019, 126, 109816.	1.2	11
99	Comparison of liquid chromatography with tandem mass spectrometry and ion-exchange chromatography by post-column ninhydrin derivatization for amino acid monitoring. <i>Clinica Chimica Acta</i> , 2019, 495, 446-450.	0.5	20
100	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. <i>Diabetes Care</i> , 2019, 42, 1593-1603.	4.3	2,101
101	Dual Role of PTPN22 but Not NLRP3 Inflammasome Polymorphisms in Type 1 Diabetes and Celiac Disease in Children. <i>Frontiers in Pediatrics</i> , 2019, 7, 63.	0.9	8
102	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodiumâ€“Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019, 42, 1147-1154.	4.3	249
103	Continuous Glucose Monitoring in 2018. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, S-13-S-31.	2.4	2
104	Continuous glucose monitoring use and glucose variability in pre-school children with type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 147, 76-80.	1.1	25
105	A randomized, multicentre trial evaluating the efficacy and safety of fastâ€“acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 961-967.	2.2	59
106	DREAM5: An openâ€“label, randomized, crossâ€“over study to evaluate the safety and efficacy of day and night closedâ€“loop control by comparing the MDâ€“Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 822-828.	2.2	29
107	Fear of hypoglycemia, anxiety, and subjective well-being in parents of children and adolescents with type 1 diabetes. <i>Journal of Health Psychology</i> , 2019, 24, 209-218.	1.3	43
108	SUN-247 Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Efficacy and Safety Results of a Randomized, Open-Label, Controlled Phase 2 Trial (REAL 3). <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	1

#	ARTICLE	IF	CITATIONS
109	Technologies in Diabetes—the Ninth ATTD Yearbook. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, S-2-S-2.	2.4	1
110	Metabolic control, ApoE genotypes, and dyslipidemia in children, adolescents and young adults with type 1 diabetes. <i>Atherosclerosis</i> , 2018, 273, 53-58.	0.4	13
111	Continuous Glucose Monitoring in 2017. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, S-13-S-29.	2.4	2
112	Medium-chain acyl-CoA dehydrogenase deficiency: Two novel <i>ACADM</i> mutations identified in a retrospective screening. <i>Journal of International Medical Research</i> , 2018, 46, 1339-1348.	0.4	5
113	Circulating levels of miR-122 and nonalcoholic fatty liver disease in prepubertal obese children. <i>Pediatric Obesity</i> , 2018, 13, 175-182.	1.4	40
114	Next generation sequencing as a follow-up test in an expanded newborn screening programme. <i>Clinical Biochemistry</i> , 2018, 52, 48-55.	0.8	52
115	Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review. <i>Atherosclerosis</i> , 2018, 277, 383-391.	0.4	73
116	ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies. <i>Pediatric Diabetes</i> , 2018, 19, 302-325.	1.2	170
117	ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. <i>Pediatric Diabetes</i> , 2018, 19, 115-135.	1.2	164
118	Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial. <i>Pediatric Diabetes</i> , 2018, 19, 1263-1270.	1.2	8
119	Non-adjunctive flash glucose monitoring system use during summer-camp in children with type 1 diabetes: The free-summer study. <i>Pediatric Diabetes</i> , 2018, 19, 1285-1293.	1.2	28
120	Continuous Glucose Monitoring Efficacy in Routine Use. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2414-2416.	1.8	3
121	Adjusting insulin doses in patients with type 1 diabetes who use insulin pump and continuous glucose monitoring: Variations among countries and physicians. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2458-2466.	2.2	44
122	Association of Glycemic Control and Cell Stress With Telomere Attrition in Type 1 Diabetes. <i>JAMA Pediatrics</i> , 2018, 172, 879.	3.3	15
123	Free-living use of artificial pancreas for children with type 1 diabetes: systematic review. <i>Diabetes Mellitus</i> , 2018, 21, 206-216.	0.5	2
124	DEPTOR promoter genetic variants and insulin resistance in obese children and adolescents. <i>Pediatric Diabetes</i> , 2017, 18, 152-158.	1.2	5
125	Striving for control: lessons learned from a successful international Type 1 Diabetes Youth Challenge. <i>Acta Diabetologica</i> , 2017, 54, 403-409.	1.2	10
126	Continuous Glucose Monitoring in 2016. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-11-S-18.	2.4	4



#	ARTICLE	IF	CITATIONS
127	Obesity, Metabolic Syndrome, and Nutrition. <i>World Review of Nutrition and Dietetics</i> , 2017, 116, 16-51.	0.1	4
128	Technologies in Diabetesâ€”The Eighth ATTD Yearbook. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-2-S-2.	2.4	1
129	Prevention of Hypoglycemia With Predictive Low Glucose Insulin Suspension in Children With Type 1 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2017, 40, 764-770.	4.3	137
130	MDâ€”Logic overnight type 1 diabetes control in home settings: <scp>A</scp> multicentre, multinational, single blind randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 553-561.	2.2	37
131	Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial. <i>Diabetologia</i> , 2017, 60, 2157-2167.	2.9	64
132	The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2017, 51, 9-13.	0.9	14
133	International Consensus on Use of Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2017, 40, 1631-1640.	4.3	1,376
134	Characterization of a de novo sSMC 17 detected in a girl with developmental delay and dysmorphic features. <i>Molecular Cytogenetics</i> , 2017, 10, 10.	0.4	3
135	Somapacitan, a onceâ€”weekly reversible albuminâ€”binding <scp>GH</scp> derivative, in children with <scp>GH</scp> deficiency: A randomized doseâ€”escalation trial. <i>Clinical Endocrinology</i> , 2017, 87, 350-358.	1.2	38
136	Autoantibody Repertoire in APECED Patients Targets Two Distinct Subgroups of Proteins. <i>Frontiers in Immunology</i> , 2017, 8, 976.	2.2	48
137	Multifocal gastric adenocarcinoma in a patient with LRBA deficiency. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 131.	1.2	33
138	3. Diagnostische Verfahren. , 2016, , .		0
139	Stabilization of Overweight and Obesity in Slovenian Adolescents and Increased Risk in Those Entering Non-Grammar Secondary Schools. <i>Obesity Facts</i> , 2016, 9, 241-250.	1.6	11
140	High-risk genotypes HLA-DR3-DQ2/DR3-DQ2 and DR3-DQ2/DR4-DQ8 in co-occurrence of type 1 diabetes and celiac disease. <i>Autoimmunity</i> , 2016, 49, 240-247.	1.2	43
141	Obesity, Metabolic Syndrome and Nutrition. <i>World Review of Nutrition and Dietetics</i> , 2016, 114, 21-49.	0.1	14
142	Diabetes Technologyâ€”Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3922-3937.	1.8	165
143	ILâ€”6â€”specific autoantibodies among APECED and thymoma patients. <i>Immunity, Inflammation and Disease</i> , 2016, 4, 235-243.	1.3	24
144	Functional Significance and Predictive Value of MicroRNAs in Pediatric Obesity: Tiny Molecules with Huge Impact?. <i>Hormone Research in Paediatrics</i> , 2016, 86, 3-10.	0.8	21

#	ARTICLE	IF	CITATIONS
145	AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies. <i>Cell</i> , 2016, 166, 582-595.	13.5	228
146	Continuous Glucose Monitoring in 2015. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, S-10-S-21.	2.4	1
147	Long-term BH4 (sapropterin) treatment of children with hyperphenylalaninemia – effect on median Phe/Tyr ratios. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2016, 29, 561-6.	0.4	9
148	Technologies in Diabetes – the Seventh ATTD Yearbook. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, S-2-S-2.	2.4	5
149	TMPRSS3 mutations in autosomal recessive nonsyndromic hearing loss. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 1151-1154.	0.8	25
150	Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 21-39.	1.7	115
151	Clinical Role of CYP2C19 Polymorphisms in Patients with Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency. <i>Acta Chimica Slovenica</i> , 2016, 63, 33-37.	0.2	2
152	Support Group for Parents Coping with Children with Type 1 Diabetes / Skupina Za Staršje Kot Podpora Druščinam Pri Sooñanju Z Otrokovno Sladkorno Boleznijo Tipa 1. <i>Zdravstveno Varstvo</i> , 2015, 54, 79-85.	0.6	7
153	Type 1 Diabetes in the Young: Organization of two National Centers in Israel and Slovenia / Sladkorna Bolezen Tipa 1 Pri Otrocih in Mladostnikih: Organizacija Dela V Dveh Nacionalnih Centrih V Izraelu in Sloveniji. <i>Zdravstveno Varstvo</i> , 2015, 54, 139-145.	0.6	8
154	Clinical, Genetic and Immunological Characteristics of Paediatric Autoimmune Polyglandular Syndrome Type 1 Patients in Slovenia / Kliniãne, Genetske in Imunoloãke Znaãilnosti Otrok In Mladostnikov Z Avtoimunskim Poliglandularnim Sindromom Tipa 1 V Sloveniji. <i>Zdravstveno Varstvo</i> , 2015, 54, 112-118.	0.6	5
155	Childhood Osteoporosis and Presentation of Two Cases with Osteogenesis Imperfecta Type V / Osteoporozã V Otroãki Dobi in Predstavitev Dveh Bolnikov Z Osteogenesis Imperfecta Tipã V. <i>Zdravstveno Varstvo</i> , 2015, 54, 119-125.	0.6	2
156	Clinical and Molecular Cytogenetic Characterisation of Children with Developmental Delay and Dysmorphic Features / Kliniãna in Molekularna Citogenetska Obravnava Otrok Z Razvojnim Zaostankom in Displastiãnimi Znaki. <i>Zdravstveno Varstvo</i> , 2015, 54, 69-73.	0.6	0
157	Annual Psychological Screening in Youth and Young Adults with Type 1 Diabetes / Letno Presejalno Psiholoãjko Testiranje Pri Mladostnikih in Mladih Odraslih S Sladkorno Boleznijo Tipa 1. <i>Zdravstveno Varstvo</i> , 2015, 54, 103-111.	0.6	3
158	Newborn Screening in Slovenia / Presejanje Novorojencev V Sloveniji. <i>Zdravstveno Varstvo</i> , 2015, 54, 86-90.	0.6	11
159	Phenylketonuria screening and management in southeastern Europe – survey results from 11 countries. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 68.	1.2	32
160	Reduced Worries of Hypoglycaemia, High Satisfaction, and Increased Perceived Ease of Use after Experiencing Four Nights of MD-Logic Artificial Pancreas at Home (DREAM4). <i>Journal of Diabetes Research</i> , 2015, 2015, 1-8.	1.0	47
161	Closed loop insulin delivery in diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2015, 29, 315-325.	2.2	34
162	Routine use of continuous glucose monitoring in 10 501 people with diabetes mellitus. <i>Diabetic Medicine</i> , 2015, 32, 1568-1574.	1.2	49

#	ARTICLE	IF	CITATIONS
163	Association of Average Telomere Length with Body-Mass Index and Vitamin D Status in Juvenile Population with Type 1 Diabetes / Povezava PovpreĀnih DolÅ¾in Telomerov Z Indeksom Telesne TeÅ¾ave in Vitaminom D Pri Mladostnikih S Sladkorno Boleznijo Tipa 1. Zdravstveno Varstvo, 2015, 54, 74-78.	0.6	8
164	Novel Mutations in <i>HESX1</i> and <i>PROP1</i> Genes in Combined Pituitary Hormone Deficiency. Hormone Research in Paediatrics, 2015, 84, 153-158.	0.8	23
165	A New Horizon for Glucose Monitoring. Hormone Research in Paediatrics, 2015, 83, 149-156.	0.8	25
166	Technologies in Diabetes – the Sixth ATTD Yearbook. Diabetes Technology and Therapeutics, 2015, 17, S-2-S-2.	2.4	0
167	Continuous Glucose Monitoring in 2014. Diabetes Technology and Therapeutics, 2015, 17, S-12-S-20.	2.4	8
168	Universal Screening for Familial Hypercholesterolemia in Children. Journal of the American College of Cardiology, 2015, 66, 1250-1257.	1.2	124
169	Comparison of tandem mass spectrometry and amino acid analyzer for phenylalanine and tyrosine monitoring – Implications for clinical management of patients with hyperphenylalaninemia. Clinical Biochemistry, 2015, 48, 14-18.	0.8	42
170	Weak association of glyoxalase 1 (GLO1) variants with autism spectrum disorder. European Child and Adolescent Psychiatry, 2015, 24, 75-82.	2.8	12
171	A case report of short-chain acyl-CoA dehydrogenase deficiency (SCADD). Biochemia Medica, 2015, 25, 279-284.	1.2	8
172	Cytogenetic and Molecular Genetic Characterization of Children with Short Stature / Citogenetska in Molekularno Genetska Opredelitev Nizke Rasti Pri Otrocih. Zdravstveno Varstvo, 2015, 54, 98-102.	0.6	2
173	Fifty-Five years of Pediatric Endocrinology and 50 years of the Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases in Slovenia / 55 Let PediatriĀne Endokrinologije in 50 Let KliniĀnega Oddelka Za Endokrinologijo, Diabetes in Presnovne Bolezni PediatriĀne Klinike. Zdravstveno Varstvo, 2015, 54, 66-68.	0.6	0
174	Obesity, Metabolic Syndrome and Nutrition. World Review of Nutrition and Dietetics, 2014, 109, 1-22.	0.1	1
175	The Role of Self-Monitoring of Blood Glucose in Patients Treated With SGLT-2 Inhibitors. Journal of Diabetes Science and Technology, 2014, 8, 783-790.	1.3	0
176	Real-Time Continuous Glucose Monitoring in Children and Adolescents. Frontiers in Diabetes, 2014, , 99-109.	0.4	1
177	Insulin treatment in children and adolescents with diabetes. Pediatric Diabetes, 2014, 15, 115-134.	1.2	111
178	Rare Single Nucleotide Polymorphisms in the Regulatory Regions of the Superoxide Dismutase Genes in Autism Spectrum Disorder. Autism Research, 2014, 7, 138-144.	2.1	23
179	Decreased prevalence of hypercholesterolaemia and stabilisation of obesity trends in 5-year-old children: possible effects of changed public health policies. European Journal of Endocrinology, 2014, 170, 293-300.	1.9	14
180	Selective Screening for Metabolic Disorders in the Slovenian Pediatric Population/Selektivni Skrining MetaboliĀkih PoremeĀjaja Kod DeĀje Populacije U Sloveniji. Journal of Medical Biochemistry, 2014, 34, 58-63.	0.7	12

#	ARTICLE	IF	CITATIONS
181	Continuous Glucose Monitoring in 2013. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, S-11-S-16.	2.4	4
182	Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis. <i>Pediatric Diabetes</i> , 2014, 15, 91-99.	1.2	93
183	Genetic risk for co-occurrence of type 1 diabetes and celiac disease is modified by HLA and killer immunoglobulin-like receptors. <i>Tissue Antigens</i> , 2014, 84, 471-478.	1.0	14
184	Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 679-687.	2.4	74
185	Technologies in Diabetes—the Fifth ATTD Yearbook. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, S-2-S-2.	2.4	1
186	Improved Metabolic Control in Pediatric Patients with Type 1 Diabetes: A Nationwide Prospective 12-Year Time Trends Analysis. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 33-40.	2.4	67
187	Impact of continuous glucose monitoring on quality of life, treatment satisfaction, and use of medical care resources: analyses from the SWITCH study. <i>Acta Diabetologica</i> , 2014, 51, 845-851.	1.2	96
188	Newborn screening in southeastern Europe. <i>Molecular Genetics and Metabolism</i> , 2014, 113, 42-45.	0.5	45
189	Fifty years of phenylketonuria newborn screening – A great success for many, but what about the rest?. <i>Molecular Genetics and Metabolism</i> , 2014, 113, 8-10.	0.5	34
190	MD-Logic Overnight Control for 6 Weeks of Home Use in Patients With Type 1 Diabetes: Randomized Crossover Trial. <i>Diabetes Care</i> , 2014, 37, 3025-3032.	4.3	158
191	Mutation analysis in mild hyperphenylalaninemia (HPA) patients – Whom and what to screen?. <i>Clinical Biochemistry</i> , 2014, 47, 236.	0.8	1
192	Two Episodes of Systemic Capillary Leak Syndrome in an 8-year-old Boy, Following Influenza A Virus Infection. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 222-224.	1.1	17
193	Influence of anti-asthmatic medications on dental caries in children in Slovenia. <i>International Journal of Paediatric Dentistry</i> , 2013, 23, 188-196.	1.0	20
194	Severe progressive obstructive cardiomyopathy and renal tubular dysfunction in Donohue syndrome with decreased insulin receptor autophosphorylation due to a novel INSR mutation. <i>European Journal of Pediatrics</i> , 2013, 172, 1125-1129.	1.3	25
195	Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice. <i>Clinical and Experimental Immunology</i> , 2013, 171, 263-272.	1.1	52
196	The incidence of type 1 diabetes in Republic of Srpska (Bosnia and Herzegovina) and Slovenia in the period 1998-2010. <i>Pediatric Diabetes</i> , 2013, 14, 273-279.	1.2	18
197	The IVS8A>G (c.913A>G) mutation and the PAH deficiency populations of Central Europe. <i>Journal of Inherited Metabolic Disease</i> , 2013, 36, 157-157.	1.7	0
198	Serum adipokines as biomarkers of beta-cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin. <i>Diabetes/Metabolism Research and Reviews</i> , 2013, 29, 166-170.	1.7	35

#	ARTICLE	IF	CITATIONS
199	Fasting and meal-stimulated residual beta cell function is positively associated with serum concentrations of proinflammatory cytokines and negatively associated with anti-inflammatory and regulatory cytokines in patients with longer term type 1 diabetes. <i>Diabetologia</i> , 2013, 56, 1356-1363.	2.9	9
200	Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp. <i>New England Journal of Medicine</i> , 2013, 368, 824-833.	13.9	397
201	Self-Monitoring of Blood Glucose in Type 2 Diabetes: Recent Studies. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 478-488.	1.3	67
202	Overnight automated type 1 diabetes control under MD-logic closed-loop system: a randomized crossover trial. <i>Pediatric Diabetes</i> , 2013, 14, n/a-n/a.	1.2	63
203	Editorial: Technologies in Diabetes – the Fourth ATTD Yearbook. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, S-2-S-2.	2.4	0
204	Continuous Glucose Monitoring in 2012. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, S-13-S-23.	2.4	4
205	Establishing a good pump clinic: successes and challenges. <i>Diabetes Management</i> , 2013, 3, 131-143.	0.5	3
206	The Role of Self-Monitoring of Blood Glucose in Glucagon-like Peptide-1-Based Treatment Approaches: A European Expert Recommendation. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 665-673.	1.3	12
207	Reimbursement for Continuous Glucose Monitoring: A European View. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 1498-1502.	1.3	42
208	Cathepsin C Gene 5' Untranslated Region Mutation in Papillon-Lefèvre Syndrome. <i>Dermatology</i> , 2012, 225, 193-203.	0.9	9
209	Assessment of tetrahydrobiopterin (BH4)-responsiveness and spontaneous phenylalanine reduction in a phenylalanine hydroxylase deficiency population. <i>Molecular Genetics and Metabolism</i> , 2012, 107, 37-42.	0.5	14
210	Five novel mutations and two large deletions in a population analysis of the phenylalanine hydroxylase gene. <i>Molecular Genetics and Metabolism</i> , 2012, 106, 142-148.	0.5	36
211	Effects of Sensor-Augmented Pump Therapy on Glycemic Variability in Well-Controlled Type 1 Diabetes in the STAR 3 Study. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 644-647.	2.4	34
212	GPR143 Gene Mutation Analysis In Pediatric Patients With Albinism. <i>Ophthalmic Genetics</i> , 2012, 33, 167-170.	0.5	5
213	The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. <i>Diabetologia</i> , 2012, 55, 3155-3162.	2.9	427
214	GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2012, 366, 433-442.	13.9	292
215	Continuous glucose monitoring in 2011. <i>International Journal of Clinical Practice</i> , 2012, 66, 8-14.	0.8	1
216	Preface. <i>International Journal of Clinical Practice</i> , 2012, 66, 1-1.	0.8	1

#	ARTICLE	IF	CITATIONS
217	Use of continuous glucose monitoring in children and adolescents *. Pediatric Diabetes, 2012, 13, 215-228.	1.2	98
218	Endothelial Nitric Oxide Synthase T(â€“786)C Polymorphism in Children and Adolescents with Type 1 Diabetes and Impaired Endothelium-Dependent Dilatation. Hormone Research in Paediatrics, 2011, 76, 248-253.	0.8	7
219	Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes. Diabetes Care, 2011, 34, 795-800.	4.3	427
220	Craniofacial characteristics and genotypes of amelogenesis imperfecta patients. European Journal of Orthodontics, 2011, 33, 325-331.	1.1	20
221	Prevalence and Incidence of Diabetes Mellitus in GH-Treated Children and Adolescents: Analysis from the GeNeSIS Observational Research Program. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1025-E1034.	1.8	60
222	The SWITCH Study (Sensing With Insulin pump Therapy to Control HbA1c): Design and Methods of a Randomized Controlled Crossover Trial on Sensor-Augmented Insulin Pump Efficacy in Type 1 Diabetes Suboptimally Controlled with Pump Therapy. Diabetes Technology and Therapeutics, 2011, 13, 49-54.	2.4	20
223	Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. European Journal of Endocrinology, 2011, 165, 401-409.	1.9	45
224	Addressing Schemes of Self-Monitoring of Blood Glucose in Type 2 Diabetes: A European Perspective and Expert Recommendation. Diabetes Technology and Therapeutics, 2011, 13, 959-965.	2.4	45
225	Preface. International Journal of Clinical Practice, 2010, 64, iii-iii.	0.8	2
226	Lack of Association of Common Allelic Variants in the Thyroglobulin Gene with Hashimotoâ€™s Thyroiditis in Young Subjects with Type 1 Diabetes. Hormone Research in Paediatrics, 2010, 73, 244-247.	0.8	2
227	STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects. Diabetes Technology and Therapeutics, 2010, 12, 249-255.	2.4	33
228	Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. Journal of Experimental Medicine, 2010, 207, 299-308.	4.2	593
229	Real-time continuous glucose monitoring in randomized control trials. Pediatric Endocrinology Reviews, 2010, 7 Suppl 3, 401-4.	1.2	1
230	Insulin pumps and continuous glucose monitoring (CGM) in preschool and school-age children: how schools can integrate technology. Pediatric Endocrinology Reviews, 2010, 7 Suppl 3, 417-21.	1.2	6
231	Genetic Polymorphisms in Genes Encoding Antioxidant Enzymes Are Associated With Diabetic Retinopathy in Type 1 Diabetes. Diabetes Care, 2009, 32, 2258-2262.	4.3	55
232	Lifetime prevalence of suicidal and self-injurious behaviors in a representative cohort of Slovenian adolescents with type 1 diabetes. Pediatric Diabetes, 2009, 10, 424-431.	1.2	35
233	Prolonged use of continuous glucose monitoring: kids do not listen - says who?. Pediatric Diabetes, 2009, 10, 89-90.	1.2	1
234	Adequate iodine intake of Slovenian adolescents is primarily attributed to excessive salt intake. Nutrition Research, 2009, 29, 888-896.	1.3	20

#	ARTICLE	IF	CITATIONS
235	Refining clinical phenotypes in septo-optic dysplasia based on MRI findings. <i>European Journal of Pediatrics</i> , 2008, 167, 1269-1276.	1.3	52
236	Detection of a complete autoimmune regulator gene deletion and two additional novel mutations in a cohort of patients with atypical phenotypic variants of autoimmune polyglandular syndrome type 1. <i>European Journal of Endocrinology</i> , 2008, 159, 633-639.	1.9	33
237	High-Dose Methylprednisolone in a Pregnant Woman with Crohn's Disease and Adrenal Suppression in Her Newborn. <i>Neonatology</i> , 2008, 94, 306-309.	0.9	37
238	Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of $\beta$ -Cell Function in Therapeutic Trials in Type 1 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1966-1971.	4.3	250
239	Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. <i>Blood</i> , 2008, 112, 2657-2666.	0.6	98
240	Clinical Use of Real-Time Continuous Glucose Monitoring. <i>Current Diabetes Reviews</i> , 2008, 4, 218-222.	0.6	25
241	Correlation Between AVPR2 Mutations and Urinary AQP2 Excretion in Patients with Nephrogenic Diabetes Insipidus. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2007, 20, 483-9.	0.4	10
242	High prevalence of thyroid peroxidase gene mutations in patients with thyroid dysmorphogenesis. <i>European Journal of Endocrinology</i> , 2007, 156, 511-519.	1.9	87
243	Iodine Intake of Slovenian Adolescents. <i>Annals of Nutrition and Metabolism</i> , 2007, 51, 439-447.	1.0	9
244	Effect of heat shock protein peptide DiaPep277 on $\beta$ -cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 276-285.	1.7	101
245	Higher frequency of the galactose-1-phosphate uridyl transferase gene K285N mutation in the Slovenian population. <i>Clinical Biochemistry</i> , 2007, 40, 414-415.	0.8	10
246	Phenotype and enamel ultrastructure characteristics in patients with ENAM gene mutations g.13185â€“13186insAG and 8344delG. <i>Archives of Oral Biology</i> , 2007, 52, 209-217.	0.8	30
247	Risk and benefits of continuous subcutaneous insulin infusion (CSII) treatment in school children and adolescents. <i>Pediatric Diabetes</i> , 2006, 7, 20-24.	1.2	23
248	Risk of Celiac Disease in Children With Type 1 Diabetes Is Modified by Positivity for HLA-DQB1*02-DQA1*05 and TNF-308A. <i>Diabetes Care</i> , 2006, 29, 858-863.	4.3	38
249	Improved Glycemic Control in Poorly Controlled Patients with Type 1 Diabetes Using Real-Time Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2006, 29, 2730-2732.	4.3	487
250	Screening Detected Celiac Disease in Children with Type 1 Diabetes Mellitus: Effect on the Clinical Course (A Case Control Study). <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2005, 41, 317-321.	0.9	59
251	A cross-sectional international survey of continuous subcutaneous insulin infusion in 377 children and adolescents with type 1 diabetes mellitus from 10 countries. <i>Pediatric Diabetes</i> , 2005, 6, 193-198.	1.2	77
252	Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia. <i>European Journal of Endocrinology</i> , 2005, 152, 869-874.	1.9	53

#	ARTICLE	IF	CITATIONS
253	Autoimmune Regulator-1 Messenger Ribonucleic Acid Analysis in a Novel Intronic Mutation and Two Additional Novel AIRE Gene Mutations in a Cohort of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4930-4935.	1.8	51
254	Galactose-1-phosphate uridyl transferase gene mutations in women with premature ovarian failure. <i>Fertility and Sterility</i> , 2005, 84, 253-255.	0.5	16
255	Motor activity during asymptomatic nocturnal hypoglycemia in adolescents with type 1 diabetes mellitus. <i>Acta Diabetologica</i> , 2004, 41, 33-37.	1.2	13
256	Insulin pump therapy for 1-6 year old children with type 1 diabetes. <i>Israel Medical Association Journal</i> , 2004, 6, 284-6.	0.1	30
257	The use of continuous subcutaneous insulin infusion (CSII) as the treatment of choice in children and adolescents with type 1 diabetes. <i>Pediatric Endocrinology Reviews</i> , 2004, 1 Suppl 3, 537-9.	1.2	1
258	A novel mutation in the G4.5 (TAZ) gene in a kindred with Barth syndrome. <i>European Journal of Human Genetics</i> , 2003, 11, 97-101.	1.4	8
259	The HLA-DRB, -DQB polymorphism and anti-insulin antibody response in Slovenian patients with type 1 diabetes. <i>International Journal of Immunogenetics</i> , 2003, 30, 223-227.	1.2	10
260	A novel L94Q mutation in the CDKN2A gene in a melanoma kindred. <i>Melanoma Research</i> , 2003, 13, 567-570.	0.6	2
261	Frequencies of Q188R and N314D Mutations and IVS5-24G>A Intron Variation in the Galactose-1-Phosphate Uridyl Transferase (GALT) Gene in the Slovenian Population. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002, 40, 1109-13.	1.4	8
262	Novel AIRE mutations and P450 cytochrome autoantibodies in Central and Eastern European patients with APECED. <i>Human Mutation</i> , 2001, 18, 225-232.	1.1	74
263	TNF $\alpha$ Decreases Gluconeogenesis in Hepatocytes Isolated from 10-Day-Old Rats. <i>Pediatric Research</i> , 2001, 49, 552-557.	1.1	22
264	Growth Patterns and Final Height in Congenital Adrenal Hyperplasia due to Classical 21-Hydroxylase Deficiency. <i>Hormone Research in Paediatrics</i> , 2001, 55, 161-171.	0.8	51
265	Lessons From 30 Years of Clinical Diagnosis and Treatment of Congenital Adrenal Hyperplasia in Five Middle European Countries. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2958-2964.	1.8	61
266	TGF- $\beta$ 2 activates genes identified by differential mRNA display in pancreatic rudiments. <i>Pflugers Archiv European Journal of Physiology</i> , 2000, 439, R26-R28.	1.3	0
267	TGF- $\beta$ 2 activates genes identified by differential mRNA display in pancreatic rudiments. <i>Pflugers Archiv European Journal of Physiology</i> , 2000, 439, r026-r028.	1.3	5
268	Insulin Tolerance during Endotoxic Shock in 10-Day-Old Rats. <i>Journal of Surgical Research</i> , 2000, 94, 75-80.	0.8	1
269	Tumor necrosis factor- $\alpha$ alters glucose metabolism in suckling rats. <i>Translational Research</i> , 1999, 133, 583-589.	2.4	14
270	TGF- $\beta$ 2 Plays a Key Role in Morphogenesis of the Pancreatic Islets of Langerhans by Controlling the Activity of the Matrix Metalloproteinase MMP-2. <i>Journal of Cell Biology</i> , 1998, 143, 827-836.	2.3	165



#	ARTICLE	IF	CITATIONS
271	TISSUE GLUCOSE TRANSPORT AND GLUCOSE TRANSPORTERS IN SUCKLING RATS WITH ENDOTOXIC SHOCK. Shock, 1996, 6, 259-262.	1.0	12
272	SARS-CoV-2 Omicron symptoms and adverse effects of GLP-1 RA therapy. Acta Diabetologica, 0, , .	1.2	0
273	Early Discovery of Children With Lysosomal Acid Lipase Deficiency With the Universal Familial Hypercholesterolemia Screening Program. Frontiers in Genetics, 0, 13, .	1.1	7